N-(4-chlorophenyl)-2-((pyridin-4-ylmethyl)thio)nicotinamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-chlorophenyl)-2-((pyridin-4-ylmethyl)thio)nicotinamide
• 英文别名: N-(4-chlorophenyl)-2-(4-pyridylmethylthio)pyridine-3-carboxamide；N-(4-chlorophenyl)-2-(pyridin-4-ylmethylthio)pyridine-3-carboxamide；N-(4-chlorophenyl)-2-(pyridin-4-ylmethylsulfanyl)pyridine-3-carboxamide
• 化学式: C₁₈H₁₄ClN₃OS
• 分子量: 355.848
• InChiKey: RJHSHBLFZBDOTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-chlorophenyl)-2-((pyridin-4-ylmethyl)thio)nicotinamide 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 2.0h， 以69%的产率得到N-(4-chlorophenyl)-2-(4-pyridylmethylsulfinyl)pyridine-3-carboxamide
  参考文献：
  名称：

  NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT

  摘要：

  公开号：

  EP1602647B1
• 作为产物：
  描述：

  2-(pyridin-4-ylmethylthio)pyridine-3-carboxylic acid 、 对氯苯胺 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以11%的产率得到N-(4-chlorophenyl)-2-((pyridin-4-ylmethyl)thio)nicotinamide
  参考文献：
  名称：

  Conformation–activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity

  摘要：

  We found 4-pyridylmethylthio derivative 1 to be very effective in using antiangiogenesis activity to prevent proliferation of HUVECs (Human Umbilical Vein Endothelial Cells), which was induced by vascular endothelial growth factor (VEGF). Compound 1 was equally effective in inhibiting VEGF receptor2 tyrosine kinase (KDR, IC50 = 26 nM). We deduced that the inhibition was the result of binding the catalytic domain of VEGF receptor2 tyrosine kinase in a similar fashion to both phthalazine derivative PTK787 2 and anthranylamide derivative AAL993 3. In this report, we will describe the conformational analyses, from ab initio MO calculation and X-ray crystallographic analyses, of compound 1 and the analogs, which include non-active 9, all in comparison with 2 and 3. The conformation-activity relationships suggest that a nonbonded intramolecular interaction between the sulfur and the carbonyl oxygen of 1 was very important in inhibiting KDR. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.068

文献信息

• α-Heteroarylation of Thioethers via Photoredox and Weak Brønsted Base Catalysis
  作者：Edwin Alfonzo、Sudhir M. Hande

  DOI：10.1021/acs.orglett.1c02151

  日期：2021.8.6

  thioethers to α-thio alkyl radicals and their addition to N-methoxyheteroarenium salts for the redox-neutral synthesis of α-heteroaromatic thioethers. Studies are consistent with a two-step activation mechanism, where oxidation of thioethers to sulfide radical cations by a photoredox catalyst is followed by α-C–H deprotonation by a weak Brønsted base catalyst to afford α-thio alkyl radicals. Further,

  我们报告了硫醚对 α-硫代烷基自由基的 C-H 活化以及它们与N-甲氧基杂芳鎓盐的加成，用于氧化还原中性合成 α-杂芳族硫醚。研究与两步活化机制一致，其中通过光氧化还原催化剂将硫醚氧化为硫化物自由基阳离子，然后通过弱 Brønsted 碱催化剂进行 α-C-H 去质子化以提供 α-硫代烷基自由基。此外，N-甲氧基杂芳鎓盐作为甲氧基自由基的来源，有助于α-硫代烷基自由基的产生和再生光氧化还原催化循环的牺牲氧化剂，发挥了额外的作用。
• Novel compounds having 4-pyridylalkylthio group as substituent
  申请人：Honda Takahiro

  公开号：US20060194836A1

  公开（公告）日：2006-08-31

  A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases in which angiogenesis or augmentation of vascular permeability is involved. In the formula, ring “A” is a benzene ring or an aromatic five- or six-memberd heterocycle which can be fused with a cycloalkane ring, “B” is alkylene, R 1 and R 2 , the same or different, are H, OH, substituted or unsubstituted alkoxy and the like, X and Y, the same or different, are group(s) selected from H, halogen, OH, substituted or unsubstituted alkoxy and the like respectively, p is 0, 1 or 2, and q is 0 or 1.

  本发明的目的是提供一种新的芳香性五元或六元杂环衍生物，其具有4-吡啶基烷硫基取代基或其盐，可作为药物使用。以下通式[I]所表示的化合物或其盐可用作治疗涉及血管生成或增强血管渗透性的疾病的治疗剂。其中，环“A”是苯环或芳香性五元或六元杂环，可以与环状烷基环融合，“B”是烷基，R1和R2，相同或不同，是H、OH、取代或未取代的烷氧基等，X和Y，相同或不同，分别是选择自H、卤素、OH、取代或未取代的烷氧基等的基团，p为0、1或2，q为0或1。
• Compounds having a 4-pyridylalkylthio group as a substituent
  申请人：Honda Takahiro

  公开号：US20090286786A1

  公开（公告）日：2009-11-19

  A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is benzene or an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R 1 and R 2 are hydrogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R 1 and R 2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.

  一种具有以下式[I]或其药学上可接受的盐的化合物：其中，A是苯或一种芳香五元杂环，该芳香五元杂环可以选择性地与环烷环融合；B是一种烷基；R1和R2是氢、羟基、烷氧基、芳基氧基、烷基、环烷基、芳基、杂环、氨基、烷基氨基、芳基氨基或酰基，或R1和R2结合形成一个杂环；X和Y是氢、卤素、羟基、烷氧基、芳基氧基、烷基、环烷基、芳基、巯基、烷硫基、芳硫基、羧基、羧酸酯、羧酰胺、氰基或硝基；p为0、1或2；q为0或1。该化合物用于治疗与血管生成或血管通透性增加有关的疾病。
• Compounds having 4-pyridylalkylthio group as substituent
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US07534802B2

  公开（公告）日：2009-05-19

  A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases in which angiogenesis or augmentation of vascular permeability is involved. In the formula, ring “A” is a benzene ring or an aromatic five- or six-memberd heterocycle which can be fused with a cycloalkane ring, “B” is alkylene, R1 and R2, the same or different, are H, OH, substituted or unsubstituted alkoxy and the like, X and Y, the same or different, are group(s) selected from H, halogen, OH, substituted or unsubstituted alkoxy and the like respectively, p is 0, 1 or 2, and q is 0 or 1.

  本发明的一个主题是提供一种新的含有4-吡啶基烷硫基取代基或其盐的芳香五元或六元杂环衍生物，其可用作药物。下列通式[I]所表示的化合物或其盐可用作治疗与血管生成或血管通透性增强有关的疾病的治疗剂。在该式中，环“A”是苯环或可与环状烷环融合的芳香五元或六元杂环，B是烷基，R1和R2，相同或不同，是氢、羟基、取代或未取代的烷氧基等，X和Y，相同或不同，分别是从氢、卤素、羟基、取代或未取代的烷氧基等中选择的基团，p为0、1或2，q为0或1。
• COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT
  申请人：Honda Takahiro

  公开号：US20120202817A1

  公开（公告）日：2012-08-09

  A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R 1 and R 2 are hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R 1 and R 2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.

  以下化合物式[I]或其药学上可接受的盐：其中A是一种芳香五元杂环，可选择与环烷基融合；B是一种烷基；R1和R2是氢、羟基、烷氧基、芳氧基、烷基、环烷基、芳基、杂环、氨基、烷基氨基、芳基氨基或酰基，或R1和R2结合形成一个杂环；X和Y是氢、卤素、羟基、烷氧基、芳氧基、烷基、环烷基、芳基、巯基、烷硫基、芳硫基、羧基、羧酸酯、羧酰胺、氰基或硝基；p为0、1或2；q为0或1。该化合物可用于治疗涉及血管生成或增强血管通透性的疾病。